Compare Bill.com Holdings Inc (BILL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Bill.com Holdings Inc trades at $48.15 (market cap $4.93B), while State Street SPDR S&P Biotech ETF trades at $159.09. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BILL | XBI | |
|---|---|---|
Market Cap | $4.93B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $56.32 | $164.28 |
52-Week Low | $31.96 | $86.92 |
Enterprise Value | $4.64B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.
Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
